Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LY2 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 6.67 | uM | 12319.167 | 0.0222 | -0.9007 | 1.2676 | |
| LY2 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 33.3 | uM | 12319.167 | 0.0047 | -0.9708 | 1.2676 | |
| MB 157 | Unknown | Unknown | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0000853 | uM | 12580.167 | 1.0307 | 1.0278 | 2.1970 | |
| MB 157 | Unknown | Unknown | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.000427 | uM | 12580.167 | 0.9970 | 0.9973 | 2.1970 | |
| MB 157 | Unknown | Unknown | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.00213 | uM | 12580.167 | 1.0293 | 1.0265 | 2.1970 | |
| MB 157 | Unknown | Unknown | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0107 | uM | 12580.167 | 1.0391 | 1.0352 | 2.1970 | |
| MB 157 | Unknown | Unknown | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0533 | uM | 12580.167 | 0.9172 | 0.9229 | 2.1970 | |
| MB 157 | Unknown | Unknown | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.267 | uM | 12580.167 | 0.8757 | 0.8827 | 2.1970 | |
| MB 157 | Unknown | Unknown | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 1.33 | uM | 12580.167 | 0.4909 | 0.4467 | 2.1970 | |
| MB 157 | Unknown | Unknown | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 6.67 | uM | 12580.167 | 0.1421 | -0.1772 | 2.1970 | |
| MB 157 | Unknown | Unknown | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 33.3 | uM | 12580.167 | 0.0341 | -0.5705 | 2.1970 | |
| MCF 10A | NM | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0000853 | uM | 11056.154 | 0.9314 | 0.9521 | 2.9341 | |
| MCF 10A | NM | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.000427 | uM | 11056.154 | 0.9490 | 0.9646 | 2.9341 | |
| MCF 10A | NM | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.00213 | uM | 11056.154 | 0.9334 | 0.9536 | 2.9341 | |
| MCF 10A | NM | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0107 | uM | 11056.154 | 1.0221 | 1.0150 | 2.9341 | |
| MCF 10A | NM | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0533 | uM | 11056.154 | 0.7353 | 0.8010 | 2.9341 | |
| MCF 10A | NM | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.267 | uM | 11056.154 | 0.6609 | 0.7367 | 2.9341 | |
| MCF 10A | NM | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 1.33 | uM | 11056.154 | 0.4573 | 0.5319 | 2.9341 | |
| MCF 10A | NM | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 6.67 | uM | 11056.154 | 0.0972 | -0.0965 | 2.9341 | |
| MCF 10A | NM | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 33.3 | uM | 11056.154 | 0.0080 | -0.6144 | 2.9341 | |
| MCF 10F | NM | - | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0000853 | uM | 12254.154 | 1.1741 | 1.2068 | 1.6307 | |
| MCF 10F | NM | - | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.000427 | uM | 12254.154 | 1.0341 | 1.0415 | 1.6307 | |
| MCF 10F | NM | - | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.00213 | uM | 12254.154 | 1.1025 | 1.1233 | 1.6307 | |
| MCF 10F | NM | - | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0107 | uM | 12254.154 | 1.0907 | 1.1094 | 1.6307 | |
| MCF 10F | NM | - | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0533 | uM | 12254.154 | 0.8899 | 0.8619 | 1.6307 |